Derigs, Patrick http://orcid.org/0000-0002-4670-8851
Schubert, Maria-Luisa
Dreger, Peter http://orcid.org/0000-0002-7429-8570
Schmitt, Anita
Yousefian, Schayan http://orcid.org/0000-0003-0902-0369
Haas, Simon http://orcid.org/0000-0001-9227-2051
Röthemeier, Caroline
Neuber, Brigitte
Hückelhoven-Krauss, Angela
Brüggemann, Monika http://orcid.org/0000-0001-5514-5010
Bernhard, Helga
Kobbe, Guido
Lindemann, Albrecht
Rummel, Mathias
Michels, Birgit
Korell, Felix
Ho, Anthony D.
Müller-Tidow, Carsten http://orcid.org/0000-0002-7166-5232
Schmitt, Michael http://orcid.org/0000-0002-1579-1509
Funding for this research was provided by:
Clinician Scientist Fellowship Program of the German Cancer Research Center (DKFZ), supported by the Dieter Morszeck Foundation
Article History
Received: 23 June 2024
Revised: 15 August 2024
Accepted: 19 August 2024
First Online: 27 August 2024
Competing interests
: AS: Travel grants from Hexal and Jazz Pharmaceuticals. Research grant from Therakos/Mallinckrodt. Consultancy BMS, Janssen‐Cilag. Co‐founder and part‐time employee of TolerogenixX LtD. of TolerogenixX Ltd. CMT: research support from Bayer AG. Advisory board member Pfizer, Janssen‐Cilag GmbH. Grants and/or provision of investigational medicinal products from Pfizer, Daiichi Sankyo, BiolineRx. MB: consulting fees from Amgen, research funding from Amgen, honoraria/ travel grants from Jazz, Celgene, Novartis, Pfizer and Amgen, advisory board member for Incyte, Amgen and AstraZeneca. MLS: consultancy for Kite/Gilead, Takeda. MS: research grants from Apogenix, Hexal and Novartis. Travel grants from Hexal and Kite. Financial support for educational activities and conferences from bluebird bio, Kite and Novartis. Advisory board member of MSD. (Co‐)PI of clinical trials of MSD, GSK, Kite and BMS. Co‐Founder and shareholder of TolerogenixX Ltd. PDe: honorarium from MSD. PDr: consultancy AbbVie, AstraZeneca, Gilead, Janssen, Novartis, Riemser, Roche; speakers bureau AbbVie, Gilead, Novartis, Riemser, Roche; research support from Neovii and Riemser. None of the mentioned sources supported the work described within this manuscript. ADH, AHK, AL, BM, BN, CR, FK, GK, HB, MR, SH, SY: none.
: All methods were performed in accordance with the relevant guidelines and regulations. The HD-CAR-1 trial was approved by the institutional review board as well as by the German federal regulatory authority for immunotherapy (Paul-Ehrlich-Institut, Langen, Germany; Eudra CT 2016-004808-60). Written informed consent was obtained from all participants. The trial was conducted in compliance with the principles of the Declaration of Helsinki.